scholarly article | Q13442814 |
P50 | author | Sam V Thambar | Q87259698 |
P2093 | author name string | Julian P Yaxley | |
P2860 | cites work | Secondary arterial hypertension: when, who, and how to screen? | Q26998998 |
A controlled trial of renal denervation for resistant hypertension | Q28236994 | ||
2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) | Q29617334 | ||
Efficacy and safety of nighttime dosing of antihypertensives: review of the literature and design of a pragmatic clinical trial. | Q33881994 | ||
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial | Q34150890 | ||
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research | Q34768060 | ||
Better blood pressure control: how to combine drugs | Q35062803 | ||
Can nocturnal hypertension predict cardiovascular risk? | Q35210578 | ||
Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability | Q35593138 | ||
Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? | Q36222792 | ||
Refractory hypertension | Q36342471 | ||
Clinical practice. Resistant or difficult-to-control hypertension | Q36548189 | ||
Prevalence and incidence of hypertension from 1995 to 2005: a population-based study | Q36642784 | ||
Nocturnal blood pressure dipping in the hypertension of autonomic failure | Q37149824 | ||
Managing hypertension using combination therapy | Q37186577 | ||
Management of patients with resistant hypertension: current treatment options | Q37304418 | ||
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial | Q39721026 | ||
The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide | Q43276884 | ||
Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial | Q44412916 | ||
Prevalence of resistant hypertension in the United States, 2003-2008. | Q46098455 | ||
Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension | Q46319417 | ||
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications | Q48217241 | ||
Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine. | Q55061463 | ||
Untreated hypertension among Australian adults: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab) | Q73717812 | ||
Effect of spironolactone on blood pressure in subjects with resistant hypertension | Q79798622 | ||
Ambulatory blood pressure monitoring | Q82378951 | ||
Resistant hypertension | Q84545128 | ||
Treatment of resistant hypertension | Q85198605 | ||
Resistant hypertension | Q85498159 | ||
P433 | issue | 2 | |
P304 | page(s) | 193-199 | |
P577 | publication date | 2015-04-01 | |
P1433 | published in | Journal of family medicine and primary care | Q27725020 |
P1476 | title | Resistant hypertension: an approach to management in primary care | |
P478 | volume | 4 |
Q92619906 | Association between Advanced Glycation End Products, Soluble RAGE Receptor, and Endothelium Dysfunction, Evaluated by Circulating Endothelial Cells and Endothelial Progenitor Cells in Patients with Mild and Resistant Hypertension |
Q47580168 | Barriers to implement screening for alcohol consumption in Spanish hypertensive patients |
Q52567741 | Noninvasive assessment of autonomic function in human neonates born at the extremes of fetal growth spectrum. |
Search more.